Investigating Transcranial Alternating Current Stimulation (tACS) Preconditioning Effects on Resting and Active Motor Threshold

September 12, 2023 updated by: University of Manitoba
Previous studies have looked at the potential of using transcranial direct current stimulation (tDCS) to prime the brain in order to lower the resting motor threshold. The resting motor threshold (RMT) is the intensity at which repeated transcranial magnetic stimulation (rTMS) is applied for treatments. The RMT is the lowest intensity at which the participant's muscle responds with the motor evoked potential peak-to-peak amplitude greater than 50μV for 5 of 10 trials when the hand is relaxed. The active motor threshold (AMT) is the lowest intensity that produces MEP with peak-to-peak amplitude greater than 100 μV for 5 of 10 trials while the participant maintains 10-30% of maximal voluntary contraction. The RMT and AMT is different for each person and the high intensity TMS pulses can be difficult for some of the patients in the current Alzheimer's rTMS treatment study to tolerate. Therefore, if the treatment can still be applied with lower intensities, it would be more tolerable for some people. The limited research on both tDCS and transcranial alternating current stimulation (tACS) in priming the brain for TMS are not enough to determine if they are effective in priming the brain. The studies that include tDCS have small sample size and inconclusive results. The studies with tACS are using very high frequencies of 140 Hz to 250 Hz. The objective of this research study is to determine if priming the brain with tACS at 40 Hz or tRNS for 10 minutes is able to reduce the resting and active motor threshold. Therefore, for people with higher RMT and AMT, priming with tACS or tRNS could be used to lower intensities while stimulating the brain for treatments.

Study Overview

Status

Terminated

Intervention / Treatment

Detailed Description

When volunteers are interested in participating in the study and they contact the PI or RA, the PI or RA will briefly explain the study. If the participant is still interested in participating, two 2-hour time slot will be scheduled for the participant to visit the lab. At the scheduled first visit, the PI or RA will provide and explain each part of the consent from. Once the participant is ready to participate, they will be asked to sign the consent form and will be provided a copy of the signed consent form. The PI or RA will assign a code to each participant. The code will be in the form of XY-RMT_##, where XY are the first letters of the first and last names and ## is a two digit number. After the consent form is signed, it will be placed in a locked cabinet located in our supervisor's office at Riverview Health Center.

Once the participant is fully enrolled, the RA and PI conduct the Montreal Cognitive Assessment (MoCA) and the Questionnaire to determine if the participant meets the inclusion criteria. If the participants have no health or physical conflicts with the application of electrical and magnetic stimulation and have a MoCA score higher than 26 out of 30, the PI and RA will set up the participant and the devices. Using our neuronavigation system in the TMS lab (at Riverview Health Center), a tracking headband will be placed on the participant and a tracker is used to measure the scalp and determine anatomical positions. Electrodes will also be placed on the participants first dorsal interosseous (FDI) muscle of the participant's right hand to record the electromyography (EMG).

The TMS device is the Magstim Rapid 2 Stimulator on single pulse setting with the figure-of-eight coil AirFilm Coil. The EMG device is the EMG Recording Pod from Brainsight 2. The tACS device is the Soterix Medical Inc. tES (transcranial electrical stimulation) (Model: 2001).

For the resting motor threshold (RMT), the PI exposes the participant's C3 section of the brain (area of the left hemisphere of the brain in 10 20 model which is related to the hand area of the primary motor cortex) to single pulses of TMS starting at 50% intensity of the maximum intensity available. This is done while the right hand is at a resting (relax) position. The RA will increase the intensity by increments of 5% until a visible twitch in the right hand is observed. Then the intensity will be decreased by decrements of 1% until 10 consistent visible twitches are observed in arrow. The minimum intensity is recorded as the RMT and the exact position and direction of the coil relative to the headband will be recorded as the target "hotspot" via the neuronavigational system (Vicra position sensor camera). The 10 consecutive successful EMGs will be recorded as the pre-priming data of the resting muscle. A similar procedure will be followed for the active motor threshold (AMT) with the only difference being the condition of the right hand. For an active recording, the participant will be asked to gently grab the arm rest of the chair so the muscle is activated 10-30% of maximal voluntary contraction and the 10 pulses will be exposed to the "hotspot as located by the Vicra camera.

To prime the brain using the tACS, the participant will be given a 5-minute break during which the RA places the active electrode of tACS on the marked "hotspot" and the reference on the contralateral supraorbital area of the head (right side of the forehead above the eyebrow). After the break, the stimulation begins at a frequency of 40 Hz and current intensity of 0.75 mA amplitude for duration of 10 minutes. Immediately after the stimulation the EMG will be recorded through 10 TMS pulses on active FDI muscle and 10 pulses with resting FDI muscle. The same procedure will be followed once 30 minutes after tACS stimulation and once after 1 hour. Similar procedure will be done for the right side RMT/AMT measurement which moves the left hand.

Overall, there will be 40 resting EMG recordings and 40 active EMG recording for each participant. The resting EMG recording will be compared at each time interval for any observable difference in average motor evoked potential (MEP) and the active EMG recordings are compared for difference in both the silence period which appears after the involuntary twitch and the MEP.

The same process will be done for a second time either 4 hours after the first session or on a different day. The only difference being that the participant receives 10 minutes of tRNS instead of tACS.

Study Type

Interventional

Enrollment (Actual)

6

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Manitoba
      • Winnipeg, Manitoba, Canada
        • Riverview Health Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 95 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

- Montreal Cognitive Assessment score greater than or equal to 26

Exclusion Criteria:

  • being pregnant
  • having any metallic implants in the head or upper body
  • having a pacemaker
  • having a history of seizures
  • having a diagnosed major psychotic disorder
  • having any nervous system medication (depression, anxiety, sleep, pain, etc.) on a daily basis
  • having a brain injury

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Participants
Each participant will have their resting and active motor threshold measured using the transcranial magnetic stimulation (TMS) device. Participants will receive tACS for 10 minutes in the first session and tRNS in the second session.
A light electrical current will be applied to the scalp of the participants via 2 electrodes. The resting and active motor threshold will be measured before, right after, after 30 minutes, and after 1 hour of receiving the tACS or tRNS.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Resting Motor Threshold
Time Frame: Before tACS, right after tACS, 30 minutes after tACS, and 1 hour after tACS
The peak-to-peak amplitude of the muscle signal from the resting motor threshold.
Before tACS, right after tACS, 30 minutes after tACS, and 1 hour after tACS

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Active Motor Threshold
Time Frame: Before tACS, right after tACS, 30 minutes after tACS, and 1 hour after tACS
Cortical silent period measured post-MEP.
Before tACS, right after tACS, 30 minutes after tACS, and 1 hour after tACS

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 16, 2022

Primary Completion (Actual)

July 1, 2023

Study Completion (Actual)

July 1, 2023

Study Registration Dates

First Submitted

August 15, 2022

First Submitted That Met QC Criteria

August 15, 2022

First Posted (Actual)

August 17, 2022

Study Record Updates

Last Update Posted (Actual)

October 6, 2023

Last Update Submitted That Met QC Criteria

September 12, 2023

Last Verified

August 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • HS25595 (B2022:070

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Understand the Effects of tACS on the Brain

Clinical Trials on tACS or tRNS and TMS

3
Subscribe